



Appendix 2

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Alexander M, Mellor JD, McArthur G, Kee D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. *Med J Aust* 2014; 201: 49-53. doi: 10.5694/mja13.10448.

Appendix 2 Patient Characteristics

	Study population n=104	Cutaneous Melanoma n=79	Mucosal Melanoma n=8	Uveal Melanoma n=11	Unknown Subtype n=6
Sex					
Male	71 (68%)	59 (75%)	3 (38%)	4 (37%)	5 (83%)
Female	33 (32%)	20 (25%)	5 (62%)	7 (63%)	1 (17%)
Age					
≤ 65	57 (55%)	44 (56%)	3 (37%)	8 (73%)	2 (33%)
> 65	47 (45%)	35 (44%)	5 (63%)	3 (27%)	4 (67%)
Melanoma					
Cutaneous	79 (76%)	79 (100%)	-	-	-
Mucosal	8 (8%)	-	8 (100%)	-	-
Uveal	11 (10%)	-	-	11 (100%)	-
Unknown Primary	6 (6%)	-	-	-	6 (100%)
M Stage					
M1a	5 (5%)	5 (6%)	-	-	-
M1b	12 (12%)	8 (10%)	3 (38%)	-	1 (17%)
M1c	87 (84%)	66 (84%)	5 (62%)	11 (100%)	5 (83%)
Brain metastases at baseline	44 (42%)	33 (42%)	3 (38%)	4 (36%)	4 (67%)
Prior Treatment					
DTIC	66 (63%)	52 (65%)	6 (75%)	2 (18%)	6 (100%)
Fotemustine	17 (16%)	11 (14%)	2 (25%)	4 (37%)	-
<i>BRAF</i> Inhibitor	4 (4%)	3 (4%)	-	1 (9%)	-
Other	4 (4%)	2 (3%)	-	2 (18%)	-
≥2 prior treatments	13 (13%)	11 (14%)	-	2 (18%)	-
Subsequent Treatments					
None	86 (82%)	68 (86%)	6 (75%)	8 (73%)	4 (67%)
Carboplatin/Paclitaxel	8 (8%)	4 (5%)	2 (25%)	-	2 (33%)
Fotemustine	2 (2%)	1 (1%)	-	1 (9%)	-
DTIC	2 (2%)	1 (1%)	-	1 (9%)	-
<i>BRAF</i> Inhibitor	1 (1%)	1 (1%)	-	-	-
Clinical Trial	3 (3%)	3 (4%)	-	-	-
Other	2 (2%)	1 (1%)	-	1 (9%)	-
LDH					
Normal	52 (50%)	42 (53%)	5 (63%)	2 (18%)	3 (50%)
Elevated	46 (44%)	32 (41%)	2 (25%)	9 (82%)	3 (50%)
Unspecified	6 (6%)	5 (6%)	1 (12%)	-	-
<i>BRAF</i> Mutation Status					
Positive	12 (12%)	11 (14%)	-	1 (9%)	-
Negative	80 (76%)	65 (82%)	7 (78%)	2 (18%)	6 (100%)
Unspecified / Not Tested	12 (12%)	3 (4%)	1 (22%)	8 (73%)	-
ECOG Performance Status					
0	31 (29%)	26 (33%)	2 (25%)	2 (18%)	1 (17%)
1	54 (52%)	41 (52%)	4 (50%)	7 (64%)	2 (33%)
2	14 (14%)	9 (11%)	1 (12.5%)	2 (18%)	2 (33%)
Unspecified	5 (5%)	3 (4%)	1 (12.5%)	-	1 (17%)

DTIC: dacarbazine, LDH: lactate dehydrogenase, ECOG: Eastern Cooperative Oncology Group